We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+44.83%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$294M
AUM Growth
+$3.65M
(+1.3%)
Cap. Flow
-$29.8M
Cap. Flow
% of AUM
-10.15%
Top 10 Holdings %
Top 10 Hldgs %
94.39%
Holding
16
New
1
Increased
5
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$7.22M |
| 2 |
Amgen
AMGN
|
+$5.21M |
| 3 |
KIN
Kindred Biosciences, Inc.
KIN
|
+$2.15M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$2.1M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$1.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
|
+$31.8M |
| 2 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$17.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $76.4M | 25.99% |
12,000,000
| – | – |
|
|
IDIX
2
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $48.2M | 16.39% |
2,000,000
-3,050,100
| -60% | -$31.8M |
|
3
Quest Diagnostics
DGX
$25.7B
| $45.5M | 15.47% |
775,000
| – | – |
|
|
BRLI
4
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $38.7M | 13.16% |
1,280,984
| – | – |
|
5
Merck
MRK
$322B
| $23.1M | 7.87% |
419,200
| – | – |
|
|
RPRX
6
DELISTED
Repros Therapeutics Inc.
RPRX
| $17.4M | 5.9% |
1,003,367
+442,767
| +79% | +$7.22M |
|
|
VVUS
7
DELISTED
Vivus Inc
VVUS
| $13.7M | 4.66% |
257,394
| – | – |
|
|
8
Amgen
AMGN
$208B
| $5.33M | 1.81% |
+45,000
| New | +$5.21M |
|
|
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $4.7M | 1.6% |
257,076
| – | – |
|
|
10
Enanta Pharmaceuticals
ENTA
$366M
| $4.52M | 1.54% |
105,000
+55,000
| +110% | +$2.1M |
|
|
KIN
11
DELISTED
Kindred Biosciences, Inc.
KIN
| $4.25M | 1.45% |
228,126
+126,301
| +124% | +$2.15M |
|
12
Labcorp
LH
$25.4B
| $3.87M | 1.32% |
44,027
| – | – |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.63M | 1.23% |
215,202
+88,507
| +70% | +$1.46M |
|
14
Gyre Therapeutics
GYRE
$641M
| $2.84M | 0.97% |
800
+382
| +91% | +$1.25M |
|
15
Traws Pharma
TRAW
$6.85M
| $1.9M | 0.65% |
6
| – | – |
|
|
MNK
16
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-274,895
| Closed | -$17.4M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, Sarissa Capital Management held 16 positions worth $294M, up 1.3% from $290M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Sarissa Capital Management withdrew a net $29.8M in Q2 2014, closing 1 position and reducing 1 holding. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $17.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Amgen worth $5.33M.
- Sarissa Capital Management's largest Q2 2014 buy was Amgen: 45,000 shares worth $5.33M.
- Sarissa Capital Management added most to Repros Therapeutics Inc. in Q2 2014, an estimated $7.22M increase.
- Sarissa Capital Management's biggest Q2 2014 reduction was IDENIX PHARMACEUTICALS INC, cutting an estimated $31.8M.
- Sarissa Capital Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q2 2014, selling an estimated $17.4M.
- Sarissa Capital Management's ten largest holdings make up 94% of its $294M portfolio in Q2 2014.
- Sarissa Capital Management opened 1 new position and closed 1 in Q2 2014.
- Sarissa Capital Management's portfolio value rose 1.3% quarter-over-quarter to $294M.
Based on Sarissa Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.